October 24, 2012
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

SymBio Announces Completion of Patient Enrollment for Phase II Clinical Trialof SyB D-0701 in RINVTOKYO, Japan, October 24, 2012 -- SymBio Pharmaceuticals Limited (JASDAQ: 4582) today
announced the completion of patient enrollment of 189 patients for its randomized double-blinded,comparative Phase II clinical trial of SyB D-0701, an antiemetic transdermal patch, for the treatment ofcancer patients with radiation-induced nausea and vomiting (RINV).

This treatment is for radiation therapy, in particular, for conventional fractionation to treat cancer
patients in combination with various anticancer agent(s), including prior to surgery. Patients can often
experience RINV during cycles of radiation treatment that lasts from a couple of days to several weeks,
resulting in an interruption of their therapy. SyB D-0701 is a sustained-release transdermal patch
containing granisetron, a commercially available 5-HT3 antagonist. Unlike currently available oral andIV formulations, the patch is designed to continuously deliver granisetron through the skin, providing thepatient with sustained relief from RINV for at least five days. Beyond RINV, further development of SyB
D-0701 is planned for chemotherapy-induced nausea and vomiting (CINV).
“We are pleased with the timely progress of this program and are excited about the potential benefits
this therapy can bring to patients who suffer from both radiation- and chemotherapy-induced nauseaand vomiting,” said Fuminori Yoshida, CEO of SymBio Pharmaceuticals. “We believe that this smallsized patch will not only improve the quality of life of patients, but also increase overall patientcompliance and thus, positive outcome for patients’ lives.”
After completion of administration of the patch to patients and data analyses, SymBio will meet with
PMDA to discuss the next steps.

[Please see the following for further information on Glossary and SymBio ][Contact]
Hiroki Maekawa
Board Director, Corporate Officer, Chief Financial Officer
Tel: +081(0)3 5472 1125

Note to Editors

GlossaryLocal radiation therapy: when high energy radiation is focused on tumors to destroy cancer cells andsuppress cancer cell growth.
Randomized double-blind comparative study: an experimental procedure in which neither the subjectsof the experiment nor the persons administering the experiment know the critical aspects of theexperiment; a double-blind procedure is used to guard against both experimenter bias and placebo
effects.
Placebo: any substance known not to have any pharmacological effect (produces no meaningfulchanges in an organism, either chemical or biological, etc.) that is made to look like an active (‘real’)
drug
Dose responsive efficacy: a range of doses over which a response occurs.

About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Ltd, established in March, 2005, by Fuminori Yoshida, who previously served
concurrently as Corporate VP of Amgen Ltd. and founding President of Amgen Japan (currently TakedaBio), aspires to be a leading commercial stage specialty pharmaceutical company in Asia Pacificdedicated to addressing underserved medical needs with main focus in the areas of oncology,
hematology and autoimmune disease. The company’s underlying corporate mission is “delivering hopeto patients in need”. SymBio’s lead drug candidate, TREAKISYM® (bendamustine hydrochloride), hasbeen successfully developed and launched in Japan for refractory/relapsed indolent non-Hodgkin’slymphoma (NHL) and mantle cell lymphoma. The company is also actively developing bendamustine inseveral Phase II trials: frontline indolent NHL, refractory/relapsed aggressive NHL (Phase II completed),and refractory/relapsed multiple myeloma in Japan. The product has been launched in Hong Kong,Singapore, Korea and Taiwan. For additional information, please visit our homepage at
http://www.symbiopharma.com.